Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Natalizumab for multiple sclerosis: a complicated treatment.

Keegan BM.

Lancet Neurol. 2011 Aug;10(8):677-8. doi: 10.1016/S1474-4422(11)70150-8. No abstract available.

PMID:
21777819
2.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
3.

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.

Hartung HP.

Lancet Neurol. 2009 Jan;8(1):28-31. doi: 10.1016/S1474-4422(08)70281-3. No abstract available.

PMID:
19081511
4.

Progressive multifocal leukoencephalopathy and natalizumab.

Hellwig K, Gold R.

J Neurol. 2011 Nov;258(11):1920-8. doi: 10.1007/s00415-011-6116-8. Epub 2011 Jun 7. Review.

PMID:
21647730
5.

Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.

Alvarez-Cermeño JC, Masjuan J, Villar LM.

N Engl J Med. 2005 Oct 20;353(16):1744-6; author reply 1744-6. No abstract available.

PMID:
16240475
6.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
7.

Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?

Maillart E, Louapre C, Lubetzki C, Papeix C.

Mult Scler. 2014 Apr;20(4):505-9. doi: 10.1177/1352458513516530. Epub 2013 Dec 23.

PMID:
24367037
8.

Natalizumab for relapsing multiple sclerosis.

Jeffery DR.

N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. No abstract available.

PMID:
16742008
9.

Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.

Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1177-8. doi: 10.1136/jnnp-2014-307582. Epub 2014 Apr 3. No abstract available.

PMID:
24700881
10.

Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.

Havla J, Hohlfeld R, Kümpfel T.

J Neurol. 2014 Jan;261(1):232-4. doi: 10.1007/s00415-013-7191-9. Epub 2013 Nov 26. No abstract available.

PMID:
24276521
11.

Natalizumab for relapsing multiple sclerosis.

Tenser RB.

N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. No abstract available.

12.

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

Kleinschmidt-DeMasters BK, Tyler KL.

N Engl J Med. 2005 Jul 28;353(4):369-74. Epub 2005 Jun 9.

13.

Natalizumab for relapsing multiple sclerosis.

Meyer MA.

N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. No abstract available.

PMID:
16742009
14.

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.

N Engl J Med. 2005 Jul 28;353(4):375-81. Epub 2005 Jun 9.

15.

Natalizumab and progressive multifocal leucoencephalopathy.

Berger JR.

Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii48-53. Review.

16.

[New drugs; natalizumab].

van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Mar 1;152(9):499-500. Review. Dutch.

PMID:
18389881
17.

Rituximab in relapsing-remitting multiple sclerosis.

Schrijver HM.

N Engl J Med. 2008 Jun 12;358(24):2645; author reply 2646-7. No abstract available.

PMID:
18557177
18.

Interruption of natalizumab therapy for multiple sclerosis: what are the risks?

Naismith RT, Bourdette D.

Neurology. 2011 May 31;76(22):1854-5. doi: 10.1212/WNL.0b013e31821d7553. Epub 2011 May 4. No abstract available.

PMID:
21543735
19.

Natalizumab and progressive multifocal leukoencephalopathy.

Adelman B, Sandrock A, Panzara MA.

N Engl J Med. 2005 Jul 28;353(4):432-3. Epub 2005 Jun 9. No abstract available.

20.

Quantitative risk-benefit analysis of natalizumab.

Steiner I.

Neurology. 2009 May 19;72(20):1791-2; author reply 1791-2. doi: 10.1212/01.wnl.0000347020.85704.36. No abstract available.

PMID:
19451538

Supplemental Content

Support Center